Company: INMB
Filing Date: 2025-09-30
Form Type: 8-K
Source: 0001213900-25-093930
Chunk: 0

Company: Inmune Bio, Inc.
Filing Date: 2025-09-30
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On September 29, 2025,
INmune Bio Inc. (the “ Company”) issued a press release announcing the submission of a manuscript, titled “ XPro1595,
a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial,”
detailing the results of the Company’s Phase 2 MINDFuL trial for peer review to npj Dementia, a Nature Portfolio journal.

A copy of the press release
is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial statements and Exhibits